MedaSorb's (MSBT.OB) Answer to Unmet Medical Need Could Be Commercialized This Year
February 08 2010 - 8:13AM
Marketwired
BioMedReports.Com, the news portal which covers Wall Street's
biomedical sector and delivers financial and investment
intelligence to a community of highly informed investors, is
reporting that MedaSorb Technologies' (OTCBB: MSBT) flagship
product CytoSorbâ„¢ -- a therapeutic device, may be a Holy Grail
which has eluded medicine for decades.
Severe sepsis is a life-threatening condition, which affects
over 18 million people each year.
"Unfortunately, most know someone who had developed a severe
infection. It could have been something as catastrophic as a
ruptured appendix, or something more common as pneumonia, maybe a
bad urinary tract infection or even influenza -- where the
infection got out of hand and sent that person to the intensive
care unit on life support, with failing critical organs like the
hearts, lungs, and kidneys," says Dr. Phillip Chan, MD, PhD, the
Chief Executive Officer of the company.
"Despite the best medical care here in the United States, one in
every three patients die of this disease, and in fact, more people
die of severe sepsis in the United States than from either heart
attacks or strokes or any single form of cancer. It remains a major
unmet medical need."
While massive resources have been invested in developing and
evaluating potential therapies, MedaSorb is conducting human trials
in Europe and has already announced preliminary positive proof of
concept in humans, using CytoSorbâ„¢ to treat severe sepsis
patients.
"Our major goal (for 2010) is the successful completion of our
trial, which will hopefully lead to CE Mark approval," Chan
said.
The complete report is available now at BioMedReports.Com:
http://biomedreports.com/articles/most-popular/27800-has-medasorb-found-the-holy-grail-to-treat-severe-infections.html
Biotech investors interested in accessing the news portal's
complete database of clinical trials and upcoming FDA decisions can
access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html
About BioMedReports.Com
BioMedReports.com is a news portal covering the biomedical news
and financial sector. BioMedReports is not paid or compensated to
report news and developments about publicly traded companies. See
our complete disclosure statements at BioMedReports.
For more biomedical sector and investment news go to
http://BioMedReports.com
Media Contact: Mary Davila Assistant Editor BioMedReports.Com
e-mail: Email Contact Tel: +1 323 472 4480 Fax: +1 888 210 3556